Mechanistic investigations now extend to pathways involving inflammation, oxidative stress, and ferroptosis.<h4>Conclusion</h4>SGLT2 inhibitors hold considerable promise in the management of kidney disease. Here, SLC5A2 is linked to kidney disorder.